Conference Coverage

Tackling grief, loss in patients with advanced lung cancer


 

Physicians experience grief, too

Patients with advanced lung cancer are not the only ones who face loss and distress. More than half of physicians treating terminally ill patients can experience burnout, according to Sonia Oyola, MD, assistant professor of family medicine at the University of Chicago Medicine.

In her presentation, Dr. Oyola highlighted strategies physicians can use to manage their grief.

The first step is simply acknowledging feelings of loss. But every physician will have a “unique way of grieving and caring for themselves,” she said.

In general, the literature supports several approaches for managing grief: engaging in death talks and self-attunement or personal awareness training as well as providing end-of-life education in medical schools.

On the personal awareness front, Dr. Oyola highlighted a narrative medicine exercise where physicians write about the patient and reflect on what moved or touched them, what surprised them, and what inspired them.

Pursuing this kind of exercise allows physicians to reflect on their experiences in a way “we often do not have the opportunity to do” and could prevent some of the “devastating consequences in our practices, such as burnout,” Dr. Oyola said.

No funding declared. Dr. Molassiotis has reported a relationship with Helsinn. No other relevant financial relationships declared.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Metformin disappoints in two phase 2 lung cancer trials
MDedge Hematology and Oncology
Microwave ablation an alternative therapy in lung malignancy
MDedge Hematology and Oncology
Finding the most bang for the buck with adjuvant atezolizumab for NSCLC
MDedge Hematology and Oncology
Unequal resource distribution underlies lung cancer disparities
MDedge Hematology and Oncology
Air pollution – second leading cause of lung cancer
MDedge Hematology and Oncology
Pandemic strategies to boost trial enrollment should stay
MDedge Hematology and Oncology
COVID is especially dangerous for mesothelioma
MDedge Hematology and Oncology
Combo treatment for NSCLC with brain metastases extends survival by two years for some
MDedge Hematology and Oncology
POSEIDON: Two ICIs plus chemo up survival in mNSCLC
MDedge Hematology and Oncology
ESMO 2021: Impressive clinical research despite pandemic
MDedge Hematology and Oncology